(10 Mar 2026, 10:36)

Jagsonpal Pharma sizzles as board to mull buyback proposal

Jagsonpal Pharmaceuticals surged 10.19% to Rs 187 after the company’s board is scheduled to meet on Thursday, 12 March 2026 to consider buyback of its fully paid up equity shares.

As on 31st December 2025, the company’s promoter shareholding stood at 67.39%.

Jagsonpal Pharmaceuticals has portfolio of drugs focusing on gynaecology, orthopaedics, dermatology and child-care segments.

The company’s standalone net profit fell 8.4% to Rs 12.49 crore on 1.5% fall in net sales to Rs 72.95 crore in Q3 FY26 compared with Q3 FY25.

More News

(10-Mar-2026 12:28)
ABB India rises after announcing $75 million investment to expand manufacturing and R&D
(10-Mar-2026 12:15)
DCM Financial Services Ltd leads gainers in 'B' group
(10-Mar-2026 12:13)
CreditAccess Grameen rises on $75 million syndicated social loan deal
(10-Mar-2026 12:00)
Authum Investment & Infrastructure Ltd leads gainers in 'A' group

More Company News View Company Information

Corporate News (10-Mar-2026 09:43)
Jagsonpal Pharmaceuticals announces board meeting date
Hot Pursuit (10-Mar-2026 10:36)
Jagsonpal Pharma sizzles as board to mull buyback proposal
Results - Announcements (22-Jan-2026 07:33)
Jagsonpal Pharmaceuticals standalone net profit declines 65.77% in the December 2025 quarter
Corporate News (14-Jan-2026 10:21)
Jagsonpal Pharmaceuticals schedules board meeting
Corporate News (06-Jan-2026 20:17)
Jagsonpal Pharmaceuticals allots 1.09 lakh equity shares under ESOP
Corporate News (18-Nov-2025 11:44)
Jagsonpal Pharmaceuticals allots 56,571 equity shares under ESOP
Results - Announcements (04-Nov-2025 07:38)
Jagsonpal Pharmaceuticals standalone net profit rises 9.69% in the September 2025 quarter

Hot Pursuit News

Jagsonpal Pharma sizzles as board to mull buyback proposal